Biocon Ltd

NSE: BIOCON · BSE: 532523 · Pharmaceuticals & Biotechnology · 69 announcements

Biocon Ltd news stories on ALFA NewsRead the news →

Share price: ₹368.05
Market cap: ₹59,981 Cr
Revenue (annual): ₹16,927 Cr
Net profit (annual): ₹385.6 Cr
P/E (TTM): 132.7×Sector 43.8×
Promoter holding: 44.68%+0.00% QoQ
FII holding: 8.64%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Other Announcement 2 Earnings Call 2 Results Update 1 Partnership 1 Management Change 1 Financial Results 1 Business Update 1 Board Meeting Date 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

1 announcement with these filters

14 Oct 2026 08:25 IST BSE

PartnershipAlfa Alert

Biocon Partnership

Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.

From: Genentech

Open announcement → Read the story on ALFA News Read the filing ↗